Press release from Marketwire
Paladin Labs Completes Strategic Partnership Transaction With Litha
Tuesday, July 03, 2012
MONTREAL, CANADA--(Marketwire - July 3, 2012) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced today that all of the conditions have been fulfilled relating to the strategic partnership transaction with the Litha Healthcare Group ("Litha"), as detailed in the press release on February 21, 2012. The transaction, as defined therein, has been completed with effect from Monday, July 2, 2012.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2011. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
Chief Financial Officer Samira Sakhia, CA, MBA Paladin Labs Inc. Tel: 514-669-5367 514-344-4675 (FAX) Email: email@example.com Website: www.paladinlabs.com